Navigation Links
First Suit Against Nobel Prize Organization Citing Defamation And Unfair Competition Practices Is Filed

LOS ANGELES, Dec. 6, 2012 /PRNewswire/ -- Dr. Rongxiang Xu, the founder of "human body regenerative restoration science" and a renowned life scientist and medical scientist, has filed a lawsuit today against The Nobel Assembly at Karolinska Institutet, a Swedish corporation, aka, Nobelforsamlingen. The Nobel Assembly at Karolinska Institutet is a body which awards the Nobel Prize in Physiology or Medicine. The suit filed in Superior Court of the State of California, Orange County Central Justice Center cites Libel and unfair competition.

Dr. Xu, one of the leading scientists in the world, discovered in 1984 the existence of "regenerative cell" which was confirmed to be keratin-19 positive stem cell after 2000 (US patent 6991813B2), during his study of burn treatments that has benefited 20 million burn victims in 73 countries, claims his good reputation in the community was defamed by a statement published by defendants, The Nobel Assembly, causing damages to Dr. Xu by their conduct. The suit alleges The Nobel Assembly has been successful in garnering media attention for their Nobel Prize announcements in essentially every major news organizations and publications world-wide, proving they can affect the perception of an individual by misreporting information.

"My main priority for filing this suit was to clarify the Academy's mistaken and misleading statements for the preservation of humanity and future generations, life science research should not desecrate the nature of human life," stated Dr. Xu.

On October 8, 2012, The Nobel Prize in Physiology or Medicine 2012 was awarded jointly to Sir John B. Gurdon and Shinya Yamanaka "for the discovery that mature cells can be reprogrammed to become pluripotent," which was covered extensively in the media. 

In an abstract published on its website made in conjunction with the selection, The Nobel Assembly described the scientists' discovery.  The Nobel Assembly claims that the scientists' discovery "represents a paradigm shift in our understanding of cellular differentiation and of the plasticity of the differentiated state."  The abstract goes on to claim that: "[t]ogether, Gurdon and Yamanaka have transformed our understanding of cellular differentiation.  They have demonstrated that the usually very stable differentiated state can be unlocked because it harbours a potential for reversion to pluripotency.  This discovery has introduced fundamentally new research areas, and offers exciting new opportunities to study disease mechanisms."

Dr. Xu believes, and alleges the Statement made by The Nobel Assembly is false as he was the scientist who made the discovery a decade earlier, therefore defaming his exemplary reputation.  The Nobel Assembly states that the scientists who won the Nobel Prize "have transformed our understanding of cellular differentiation" because "[t]hey have demonstrated that the usually very stable differentiated state can be unlocked because it harbours a potential for reversion to pluripotency."  Those scientists did not demonstrate as such.  It was ten years earlier that Dr. Xu made that discovery when he was able to explain how his discovery unlocked a somatic cell's potential to revert to pluripotent stem cell in situ. 

The Nobel Assembly's use of the word "unlocked" compounds the falsity of the statement because it suggests that the scientists who won the Nobel Prize are harnessing an inherent ability of a somatic cell to revert to its pluripotent state through natural means that do not alter the cells integrity. If the Nobel Prize scientists' findings consisted of leaving a somatic cell intact and unmodified, such as Dr. Xu's finding, then the Statement would have been true and accurate.  However, the Nobel Prize scientists' discovery actually consists of the creation of an altered cell having nothing to do with human body pluripotent stem cell.  The Academy also falsely stated that "[t]his discovery has introduced fundamentally new research areas, and offers exciting new opportunities to study disease mechanisms" which is also inaccurate.

The Statements made by the defendant has tainted and damaged Dr. Xu's achievements in the eyes of the scientific community, business, potential investors and his ability to continue to be selected as a top keynote speaker for several major international conferences.

The Plaintiff is represented by the Ardent Law Group in California, case number:  30-2012-00615804. Please contact Jane Westgate 336.608.4439 or Cheryl Riley 703.683.1798.

SOURCE Mebo International
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. Karmanos Cancer Center first in Midwest to offer latest Molecular Breast Imaging
3. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
4. First Effective Treatment For Traumatic Brain Injury Reported by Institute of Neurological Recovery, Even Years After Injury
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
6. First noiseless single photon amplifier
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
8. Elektas Monaco System Used for First Time to Create VMAT Plan for Delivery on Varian Treatment System
9. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
10. First Neurally Controlled, Powered Prosthetic Limb Is 2,109 Steps Closer To Realization
11. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):